BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32267475)

  • 1. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
    Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
    JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
    Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
    JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
    Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
    J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
    Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
    Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
    Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
    Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.
    Roberts ME; Riegert-Johnson DL; Thomas BC; Thomas CS; Heckman MG; Krishna M; DiCaudo DJ; Bridges AG; Hunt KS; Rumilla KM; Cappel MA
    J Genet Couns; 2013 Jun; 22(3):393-405. PubMed ID: 23212176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Muir-Torre syndrome and Turcot syndrome].
    Velter C; Caussade P; Fricker JP; Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Female patient with Muir-Torre syndrome].
    Negraszus N; Jöhrens K; Bertelmann E
    Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
    Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
    Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
    Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
    Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.
    Walsh MD; Jayasekara H; Huang A; Winship IM; Buchanan DD
    Australas J Dermatol; 2019 May; 60(2):126-133. PubMed ID: 30506759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.
    Cesinaro AM; Ubiali A; Sighinolfi P; Trentini GP; Gentili F; Facchetti F
    Am J Dermatopathol; 2007 Aug; 29(4):351-8. PubMed ID: 17667167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
    Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
    Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores.
    ; Vidal CI; Sutton A; Armbrect EA; Lee JB; Litzner BR; Hurley MY; ; Alam M; Duncan LM; Elston DM; Emanuel PO; Ferringer T; Fung MA; Hosler GA; Lazar AJ; Lowe L; Plaza JA; Robinson JK; Schaffer A
    J Cutan Pathol; 2019 Jul; 46(7):484-489. PubMed ID: 30895633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
    Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
    Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
    Chhibber V; Dresser K; Mahalingam M
    Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.